Host defenses against zygomycetes

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 1, 2012, Pages

  Roilides, Emmanuel ^a   Kontoyiannis, Dimitrios P ^b   Walsh, Thomas J ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; IN VIVO STUDY; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; ZYGOMYCETES;

ANIMALS; ANTIFUNGAL AGENTS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MACROPHAGES, ALVEOLAR; MUCORALES; NEUTROPHILS; OXIDATION-REDUCTION; PHAGOCYTES; RISK FACTORS; SPECIES SPECIFICITY; SPORES, FUNGAL; ZYGOMYCOSIS;

EID: 84855874847     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir869     Document Type: Article

References (43)

1. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53. (Pubitemid 41170352)
2. Lanternier F, Lortholary O. Zygomycosis and diabetes mellitus. Clin Microbiol Infect 2009;15(Suppl 5):21-5.
3. Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and children. Clin Microbiol Infect 2009;15(Suppl 5):50-4.
4. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;50:1091-100.
5. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009;15:1395-401.
6. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazoleassociated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009;15(Suppl 5):93-7.
7. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect 2009;15(Suppl 5):2-9.
8. Antoniadou A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect 2009;15(Suppl 5):55-9.
9. Netea MG, Van der Meer JW, Kullberg BJ. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clin Microbiol Infect 2006;12:404-9.
10. Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109:33-44. (Pubitemid 30608735)
11. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998;92:3007-17. (Pubitemid 28492304)
12. De Lucca AJ, Walsh TJ. Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 1999;43:1-11. (Pubitemid 29069190)
13. Ramanathan B, Davis EG, Ross CR, Blecha F. Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. Microbes Infect 2002;4:361-72. (Pubitemid 34293642)
14. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002;23:291-6. (Pubitemid 34628771)
15. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004;4:1-23.
16. Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun 1982;38:487-95. (Pubitemid 12002663)
17. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophilmediated activity against opportunistic fungal pathogens. J Infect Dis 1997;175:1012-5. (Pubitemid 27142990)
18. Warris A, Netea MG, Verweij PE, et al. Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to Aspergillus fumigatus and other filamentous fungi. Med Mycol 2005;43:613-21. (Pubitemid 43084518)
19. van de Veerdonk FL, Kullberg BJ, van der Meer JW, Gow NA, Netea MG. Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol 2008;11:305-12.
20. Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through Toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 2008;52:722-4. (Pubitemid 351170850)
21. Chamilos G, Lewis RE, Hu J, et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A 2008;105:9367-72.
22. Cortez KJ, Lyman CA, Lempicki R, et al. Comparative functional genomics of innate host defense molecules in human monocytes infected with Aspergillus fumigatus and Rhizopus oryzae [abstract M-1773/393]. In: 46th Interscience Conference Antimicrobial Agents and Chemotherapy. San Francisco, CA: American Society for Microbiology, 2006:438.
23. Ma LJ, Ibrahim AS, Skory C, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009;5:e1000549.
24. Brieland JK, Jackson C, Menzel F, et al. Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus. Infect Immun 2001;69:1554-60. (Pubitemid 32187608)
25. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005;191:1180-7. (Pubitemid 40404378)
26. Demchok JP, Meletiadis J, Stergiopoulou T, et al. Bliss independence interaction analysis of the inhibitory effects of hydrocortisone and glucose on human neutrophil mediated hyphal damage to Rhizopus oryzae [abstract M-1584]. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and the 46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC: American Society for Microbiology, 2008:654.
27. Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol 2005;129:583-96. (Pubitemid 40825819)
28. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997;24:192-6. (Pubitemid 27081542)
29. Safdar A. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist 2007;12(Suppl 2):2-6.
30. Sahin B, Paydas S, Cosar E, Bicakci K, Hazar B. Role of granulocyte colony-stimulating factor in the treatment of mucormycosis. Eur J Clin Microbiol Infect Dis 1996;15:866-9. (Pubitemid 26421620)
31. Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NK, Neglia JP. Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 1994;34:226-32. (Pubitemid 24109648)
32. Dignani MC, Dignani MC, Anaissie EJ, et al. Treatment of neutropeniarelated fungal infections with granulocyte colony-stimulating factorelicited white blood cell transfusions: a pilot study. Leukemia 1997;11:1621-30. (Pubitemid 27458598)
33. Briones MA, Josephson CD, Hillyer CD. Granulocyte transfusion: revisited. Curr Hematol Rep 2003;2:522-7.
34. Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica 2009;94:1661-8.
35. Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2009; (1): CD005341.
36. Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukemia-new drugs and immunotherapy. Best Pract Res Clin Haematol 2008;21:683-90.
37. Pursell K, Verral S, Daraiesh F, et al. Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: in vitro effect of r-metHuG-CSF (Filgrastim). Transpl Infect Dis 2003;5:29-37. (Pubitemid 36705902)
38. Rodriguez MM, Calvo E, Marine M, Pastor FJ, Fernandez-Ballart J, Guarro J. Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice. Antimicrob Agents Chemother 2009;53:3569-71.
39. Saoulidis S, Simitsopoulou M, Dalakiouridou M, Papaioannidou P, Roilides E. Antifungal activity of posaconazole and granulocyte colony-stimulating factor in the treatment of disseminated zygomycosis in a neutropenic murine model. Intern J Infect Dis 2008;12(Suppl 2): S48.
40. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008;47:226-35. (Pubitemid 351952889)
41. Simitsopoulou M, Roilides E, Maloukou A, Gil-Lamaignere C, Walsh TJ. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses 2008;51:147-54. (Pubitemid 351191114)
42. Simitsopoulou M, Georgiadou E, Walsh TJ, Roilides E. Cunninghamella bertholletiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp. Med Mycol 2010;48:720-4.
43. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and Non-Aspergillus Hyphae. J Infect Dis 2008;198:186-92. (Pubitemid 352019283)